Hepatitis C is the “favorite child” of current medical ethics discussions. However, the new, expensive HCV drugs should not cloud the view of the overall diagnostic and therapeutic situation of the condition. Screening of at-risk populations and correct interpretation of test results remain important. This also applies to hepatitis B.